Ignyta Announces Preliminary Data From RXDX-101 Phase 1 Clinical Trial
2/21/2014 8:57:53 AM
SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (OTCQB:RXDX), an oncology precision medicine biotechnology company, announced today that Justin Gainor, M.D., of the Massachusetts General Hospital Cancer Center, presented preliminary results from the ongoing Phase 1 dose escalation portion of a Phase 1/2 clinical trial of RXDX-101, Ignyta’s proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, at the International Association for the Study of Lung Cancer (IASLC) 14th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting. The trial is ongoing, with final results for the Phase 1 portion of the trial expected later this year.
Help employers find you! Check out all the jobs and post your resume.
comments powered by